| Code | CSB-RA018727MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to rolinsatamab, designed for research targeting the prolactin receptor (PRLR). PRLR is a type I cytokine receptor that mediates the biological effects of prolactin, a hormone critical for mammary gland development, lactation, reproduction, and immune regulation. The receptor signals primarily through the JAK2/STAT5 pathway and plays important roles in cellular proliferation and differentiation. Aberrant PRLR expression and signaling have been implicated in various malignancies, particularly breast cancer, where elevated PRLR levels correlate with tumor progression and therapeutic resistance. The receptor is also associated with prostate cancer, endometrial cancer, and certain hematological malignancies.
Rolinsatamab is a therapeutic antibody developed to target PRLR-expressing tumors by blocking prolactin-receptor interactions and inhibiting downstream oncogenic signaling. This biosimilar provides researchers with a valuable tool for investigating PRLR biology, exploring prolactin-dependent signaling mechanisms, and studying the receptor's role in cancer pathogenesis and progression. It supports oncology research, endocrine studies, and therapeutic development programs focused on PRLR-targeted interventions.
There are currently no reviews for this product.